Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490252 | 1.00 | POLB (0.54) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL12136691 | 0.84 | RAB9A (0.57) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL9388512 | 0.82 | POLB (0.53) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL22862551 | 0.82 | POLB (0.53) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL29490174 | 0.82 | POLB (0.53) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL7479892 | 0.82 | POLB (0.53) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL13156353 | 0.82 | POLB (0.53) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31737865 | 0.81 | POLB (0.51) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL13633144 | 0.79 | POLB (0.50) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL17229324 | 0.79 | BRD4 (0.51) | POLBSMN1; SMN2TSHRL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | POLB 1716/4885SMN1; SMN2 2633/4885TSHR 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.